Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24179625 | 1.00 | SIGMAR1 (0.47) | SIGMAR1TMEM97NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30053112 | 1.00 | SIGMAR1 (0.47) | SIGMAR1TMEM97NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30052834 | 1.00 | SIGMAR1 (0.47) | SIGMAR1TMEM97NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29148961 | 1.00 | SIGMAR1 (0.47) | SIGMAR1TMEM97NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28540053 | 1.00 | SIGMAR1 (0.47) | SIGMAR1TMEM97NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16409317 | 0.89 | SIGMAR1 (0.46) | SIGMAR1TMEM97NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29148988 | 0.89 | SIGMAR1 (0.46) | SIGMAR1TMEM97NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29148979 | 0.89 | SIGMAR1 (0.46) | SIGMAR1TMEM97NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29213769 | 0.89 | SIGMAR1 (0.46) | SIGMAR1TMEM97NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17782309 | 0.89 | SIGMAR1 (0.46) | SIGMAR1TMEM97NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578053-B2 | Chemical process for preparing phenylpiperidinyl indole derivatives | NOVARTIS AG (CH) | 2023-02-14 | — | — | US | disclosed |
| US-20220169630-A1 | CHEMICAL PROCESS FOR PREPARING PHENYLPIPERIDINYL INDOLE DERIVATIVES | NOVARTIS AG (CH) | 2022-06-02 | — | — | US | disclosed |
| CN-112513025-A | Chemical process for the preparation of phenylpiperidinylindole derivatives | 诺华股份有限公司 | 2021-03-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169630-A1 | CHEMICAL PROCESS FOR PREPARING PHENYLPIPERIDINYL INDOLE DERIVATIVES | IDO1, CYP3A7, PAH | SIGMAR1 1700/4885TMEM97 3511/4885NPC1 1271/4885 |
| US-11578053-B2 | Chemical process for preparing phenylpiperidinyl indole derivatives | IDO1, CYP3A7, PAH | SIGMAR1 1700/4885TMEM97 3511/4885NPC1 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.